Jefferies analyst Kelly Shi lowered the firm’s price target on PTC Therapeutics (PTCT) to $63 from $64 and keeps a Buy rating on the shares after the company received a complete response letter for vatiquinone in Friedreich’s ataxia from the FDA. The firm had a low expectation going into the PDUFA deadline, so the CRL “didn’t come in as a surprise to us,” says the analyst, who calls the regulatory update “a clearing event” that allows investors to now focus on the launch in phenylketonuria and the path forward in Huntington’s disease. The firm lowered its view of the odds of success in FA to 5%, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- RBC says PTC Therapeutics CRL may signal difficulty for Biohaven
- PTC Therapeutics CRL ‘expected,’ focus moves to Sephience, says RBC Capital
- PTC Therapeutics: Buy Rating Maintained Despite Vatiquinone Setback
- PTC Therapeutics price target lowered to $50 from $56 at TD Cowen
- PTC Therapeutics: Hold Rating Amid Regulatory Setbacks and Sephience Growth Potential